FLT3 and acute myeloid leukemia: The N-indolocarbazole, midostaurin (PKC412; N-benzoyl-staurosporine; Novartis Pharma AG) was shown to target oncogenic FLT3 in preclinical studies [6] was reported to significantly prolong survival of FLT3-mutated AML patients when combined with conventional induction and consolidation therapies in a randomized Phase III clinical trial [7].